Atara Biotherapeutics (ATRA) EBITDA Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly EBITDA Margin came in at 652.91% in Q1 2026, down 69244.0% YoY from N/an in Q1 2025, and down 306.32% on a QoQ basis from 160.69% in Q4 2025.
Atara Biotherapeutics (ATRA) EBITDA Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 6 years of EBITDA Margin data on file, last reported at 652.91% in Q1 2026.
- Quarterly EBITDA Margin fell 69244.0% year-over-year to 652.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.27% (down 2056.0% YoY) and the FY2025 annual result came in at 29.69%, up 9440.0% from the prior year.
- EBITDA Margin slipped to 652.91% in Q1 2026, from 160.69% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1992.09% in Q4 2023 to a low of 43545.12% in Q2 2023.
- A 5-year average of 3802.16% and a median of 108.86% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 4348283 bps — and 2024, when it surged 4348147 bps.
- Tracing ATRA's EBITDA Margin over 5 years: stood at 4260.52% in 2022, then soared by 147 bps to 1992.09% in 2023, then sank by 102 bps to 37.26% in 2024, then tumbled by 331 bps to 160.69% in 2025, then plunged by 306 bps to 652.91% in 2026.
- The last three EBITDA Margin figures came in at 652.91% (Q1 2026), 160.69% (Q4 2025), and 103.5% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | -749.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -749.21% |
| Mar 31, 2026 | -652.91% |
| Dec 31, 2025 | -160.69% |
| Sep 30, 2025 | -103.50% |
| Jun 30, 2025 | 18.19% |
| Mar 31, 2025 | 39.53% |
| Dec 31, 2024 | -37.26% |
| Sep 30, 2024 | -54.14% |
| Jun 30, 2024 | -63.66% |
| Mar 31, 2024 | -114.22% |
| Dec 31, 2023 | 1,992.09% |
| Sep 30, 2023 | -3,446.14% |
| Jun 30, 2023 | -43,545.12% |
| Mar 31, 2023 | -8,486.20% |
| Dec 31, 2022 | -4,260.52% |
| Sep 30, 2022 | -1,897.78% |
| Jun 30, 2022 | -62.30% |
| Dec 31, 2021 | -1,237.45% |
| Sep 30, 2021 | -1,579.37% |
| Jun 30, 2021 | -2,170.59% |